Literature DB >> 20406663

Mucosal vaccination with a codon-optimized hemagglutinin gene expressed by attenuated Salmonella elicits a protective immune response in chickens against highly pathogenic avian influenza.

Karen A Liljebjelke1, Daniel I Petkov, Darrell R Kapczynski.   

Abstract

The purpose of this study was to evaluate clinical protection from challenge conferred by two attenuated Salmonella enteria serovar typhimurium vaccine strains expressing the hemagglutinin (HA1) gene from a highly pathogenic avian influenza (HPAI) H5N1 (A/whooper swan/Mongolia/3/2005), under control of the anaerobically inducible nir15 promoter. Two-week-old White Leghorn chickens were immunized by oral gavage with one milliliter doses of >109 Salmonella colony-forming units once weekly for 4 weeks prior to challenge. Expression of recombinant protein was confirmed via Western blot. Serum and mucosal gavage samples were collected prior to, and following immunization and antibodies against avian influenza HA were confirmed by Western blot and hemagglutination-inhibition (HI) assay. Chickens were challenged with homologous (A/whooper swan/Mongolia/3/2005), or heterologous (A/Chicken/Queretaro/14588-19/95) HPAI virus strains. Chickens immunized with attenuated Salmonella strains containing plasmid expression vector (pTETnir15HA) demonstrated a statistically significant increase in survival compared to control groups. Results provide evidence of effectiveness of attenuated Salmonella strains for delivery of recombinant avian influenza HA antigens and induction of mucosal and systemic immune responses protective against lethal challenge with HPAI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406663     DOI: 10.1016/j.vaccine.2010.04.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Improving the efficiency of transposon mutagenesis in Salmonella enteritidis by overcoming host-restriction barriers.

Authors:  Turki M Dawoud; Tieshan Jiang; Rabindra K Mandal; Steven C Ricke; Young Min Kwon
Journal:  Mol Biotechnol       Date:  2014-11       Impact factor: 2.695

2.  Comparative immunological evaluation of recombinant Salmonella Typhimurium strains expressing model antigens as live oral vaccines.

Authors:  Song-yue Zheng; Bin Yu; Ke Zhang; Min Chen; Yan-Hong Hua; Shuofeng Yuan; Rory M Watt; Bo-Jian Zheng; Kwok-Yung Yuen; Jian-Dong Huang
Journal:  BMC Immunol       Date:  2012-09-26       Impact factor: 3.615

3.  Attenuated Salmonella typhimurium SV4089 as a potential carrier of oral DNA vaccine in chickens.

Authors:  Seyed Davoud Jazayeri; Aini Ideris; Zunita Zakaria; Abdul Rahman Omar
Journal:  J Biomed Biotechnol       Date:  2012-06-04

4.  Oral Delivery of a Novel Attenuated Salmonella Vaccine Expressing Influenza A Virus Proteins Protects Mice against H5N1 and H1N1 Viral Infection.

Authors:  Zenglin Pei; Xiaohong Jiang; Zhu Yang; Xiaoguang Ren; Hao Gong; Michael Reeves; Jingxue Sheng; Yu Wang; Zishu Pan; Fenyong Liu; Jianguo Wu; Sangwei Lu
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

5.  Live attenuated H5N1 vaccine with H9N2 internal genes protects chickens from infections by both highly pathogenic H5N1 and H9N2 influenza viruses.

Authors:  Nguyen Tai Nang; Byung Min Song; Young Myong Kang; Heui Man Kim; Hyun Soo Kim; Sang Heui Seo
Journal:  Influenza Other Respir Viruses       Date:  2012-04-09       Impact factor: 4.380

6.  Oral Delivery of a DNA Vaccine Expressing the PrM and E Genes: A Promising Vaccine Strategy against Flavivirus in Ducks.

Authors:  Juan Huang; Renyong Jia; Haoyue Shen; Mingshu Wang; Dekang Zhu; Shun Chen; Mafeng Liu; Xinxin Zhao; Ying Wu; Qiao Yang; Zhongqiong Yin; Anchun Cheng
Journal:  Sci Rep       Date:  2018-08-17       Impact factor: 4.379

7.  Isolation of recombinant phage antibodies targeting the hemagglutinin cleavage site of highly pathogenic avian influenza virus.

Authors:  Jinhua Dong; Akira Sakurai; Namiko Nomura; Enoch Y Park; Futoshi Shibasaki; Hiroshi Ueda
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.